GC Cell said Tuesday that a research team led by Professor Jung Min-kyu at Severance Hospital has initiated ﬁrst patient dosing (FPI) in an advanced regenerative medicine clinical study evaluating the HER2-targeted CAR-NK cell therapy candidate AB-201

AB-201 - Artiva Biotherapeutics

May 19, 2026